Full Title
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsPurpose
Researchers are assessing different doses of AB248 to use alone and with pembrolizumab in people with advanced cancers. The people in this study have solid tumors that have spread and gotten worse, even with treatment.
AB248 is a modified form of a protein called interleukin-2, which is normally made by the immune system. AB248 is designed to selectively increase the activity of immune cells to help your body destroy cancer cells.
Pembrolizumab is an immunotherapy that takes the brakes off the immune system, boosting its power to find and kill cancer cells. Researchers believe both drugs used together may work better than either one alone. Both AB248 and pembrolizumab are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a solid tumor that has spread and gotten worse even after treatment.
- Have completed prior anti-cancer medications at least 4 weeks before getting the study therapy.
- Have recovered from the serious side effects of previous therapies before the study treatment is given.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.